PHP355 Impact of Decision Making Based on The Matching The Quality of The Early Warning Indicators In Colombia During 2013 – 2014 Between Private And Public Ips and The Quantity of Affiliates By Regimen  by Ordoñez Castillo, JA & Garcia Pulido, IJ
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A575
PHP354
Considering evidenCe From HealtH eConomiCs WitHin immunization 
deCision-making - a semi multiPle Criteria deCision aPProaCH using 
tHe deCide tool
Ultsch B, Wichmann O, Harder T
Robert Koch Institute, Berlin, Germany
BAckground: mmunization decision-making (IDM) should draw on high qual-
ity evidence from various sources such as health economics (HE). Objective of 
this study was to test the applicability of a framework that enables a systematic, 
transparent, and evidence based IDM based on multiple criteria. Method: We 
applied the ‘Evidence to Decision (EtD) Framework’ developed by the ‘Developing 
and Evaluating Communication Strategies to Support Informed Decisions and 
Practice Based on Evidence’ (DECIDE) collaboration to the example of vaccination 
against pneumococcal-disease (PD) in adults and utilized HE evidence from a mod-
eling study for Germany. We tested how EtD criteria can be operationalized for the 
development of a specific IDM on which HE was expected to have a strong impact. 
A panel of members of the Methods-Working-Group of the German standing com-
mittee on vaccination (STIKO) was asked to use the EtD framework and judge on its 
applicability and usefulness for IDM. results: Data from the HE model were used 
to inform one out of six criteria (disease-burden, evidence quality, magnitude of 
effects, balance of effects, cost-effectiveness, acceptability) of the EtD framework. 
Since two vaccine-types (23-valent polysaccharide and 13-valent conjugate vac-
cine [PPSV23, PCV13]) were compared in the HE model, judgement options for the 
HE criterion were: ‘favors PPSV23’; ‘favors PCV13’; ‘favors sequential vaccination 
PCV13&PPSV23’; ‘does not favor either’; ‘favors no vaccination’. Panel-members 
reported the usefulness of the EtD framework for IDM on PD vaccination, especially 
regarding the integration of HE result-figures. discussion: The EtD framework 
seems very suitable to consider HE in evidence based IDM even in a complex 
situation where multiple vaccination strategies are compared. It’s in particular 
helpful to communicate HE results-figures to non-economists and supports trans-
parency in IDM. In the project ‘Standardization of healTh Economic Evaluations 
of vaccINes in Germany’ (STEErING) the integration of HE in IDM will be further 
explored.
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oBjectives: The objective of the present study was assess the impact of the 
performance evaluation, in terms of quality of the early warning indicators in 
Colombia during 2013 – 2014 between private and public IPS and the quantity of 
affiliates. The quality has been established as a key attribute in the comprehensive 
health care, which under the General System of Social Security in Health(SGSSS) 
in the Act100 of 1993 and the reforms of Decree1011 of 2006 and Resolution1446 
of the same year, was designed and implemented the policy of the system of 
warranties of quality in health care, in terms of quality of the early warning 
indicators(EWI). Methods: A GLM and matching analysis comparing the quality 
in terms of timeliness and accessibility of health(TAH) care in the health insti-
tutions by department between 2013-2014 is proposed, taking into account the 
participation of affiliates in the contributory and subsidized regimen(CR-SR), in 
order to show that the number of members of the SGSSS at the departmental level 
is not necessarily determined by the increased presence of IPS or health centers 
or by the quality results of TAH. results: The period studied, after running nine 
models of linear regression intertwined variables mentioned above (n_obs= 33), it 
was shown that members of the SR(SR”n2013= 22669543;n2014= 22882669”;&;CR”
n2013= 20150266;n2014= 20760123”)had a correlation of 30.63%compared to public 
regardless of private-IPS , while the worst correlation 7.54 %was manifested in 
the SRmembers attending Pr-IPS, since a high degree of omitted variables Pu-Pr-
IPS manifests48.66%. conclusions: SR had a notable effect over the quantity 
of affiliates in the health system. Affiliates of both Regimens prefer to assist to 
pu-IPS considering that had the highest quality(EWI). This research will open the 
discussion about the relevance of quality indicators in health and their relation 
with national budget, and what will happen if Colombia implement a Universal 
Health System.
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PrevalenCe oF HePatitis C and PresenCe oF ComorBidities in sWeden: 
a nationWide PoPulation-Based register study
Büsch K, Kövamees J, Söderholm J
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oBjectives: The aim of the study was to estimate the prevalence of chronic hepati-
tis C (CHC) using Swedish nationwide register data. The secondary objective was to 
describe the presence of comorbidities compared with matched general population 
controls. Methods: Patients were identified according to international classifica-
tion codes (ICD) for hepatitis C (HCV) in inpatient care (1987–2013), day surgery and 
non-primary outpatient care (1997–2013) in the nationwide Swedish Patient Register. 
The prevalence of CHC was defined as cumulative prevalence, and calculated as 
the number of patients alive and resident in Sweden Dec 31st 2013 with a diagnosis 
listings for CHC during the study period divided by the total Swedish population 
on that date (n= 9 644 864). Five general population controls were matched by age, 
sex, and county of residence to each CHC patient. Presence of co-morbidities were 
ascertained from the same register after CHC diagnosis and compared with matched 
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In 2010, the Ministry of Health (MoH) requested USAID for technical assis-
tance to implement interventions to improve the HIV/AIDS supply chain sys-
tem. Assessments revealed that fragmentation of the pharmaceutical system 
contributed to stock-outs and expiration of antiretroviral (ARVs) and other 
medicines and supplies used by disease control programs (DCPs). The imple-
mentation of an integrated system was proposed as the most efficient and sus-
tainable alternative to confront the HIV/AID pharmaceutical supply problems. 
Since 2011, the MoH with the support of USAID partners is integrating vertical 
DCP systems –including Tuberculosis and HIV/AIDS- into a single pharmaceuti-
cal management system (SUGEMI, in Spanish). The implementation of SUGEMI 
included: (1) an evidence-based for the design of the system and implemen-
tation of particular interventions; (2) institutional strengthening of national 
and regional implementing units; (3) legal support through Ministry and 
Presidential Decrees; (4) development and implementation of standard operating 
procedures (SOPs). Since 2014, the HIV/AIDS program has moved the ARVs from 
program specific stores to integrated warehouses; their personnel is using stand-
ardized SUGEMI formularies for requisition and delivery; and, has participated in 
national forecasting exercises leading to the procurement of quantities of ARVs, 
closer to the estimated needs of the patients. As a result of these interventions in 
2014 and 2015, the availability of ARVs has increased from 40% to a 97% in health 
facilities and 70% to a 100% in central warehouse. Simultaneous interventions in 
various pharmaceutical management components, within an integrated national 
pharmaceutical system have contributed to increase the availability of ARVs in 
the Dominican public health system.
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The Ministry of Health of Turkey has a system that places a high value on improv-
ing health care in all areas. The Ministry has initiated a project called “Health 
Transition” which has some sub-components to provide the above-mentioned 
goal . A number of national priorities have been established for these components 
one of which is to address health technology assessment (HTA). Health technology 
covers a variety of practices including pharmaceuticals, medical devices, surgical 
methods and health systems that are used for protecting and promoting health; 
and preventing, diagnosing and curing of diseases. Health Economics and in par-
ticular HTA is also a high priority for the European Union (EU) as stated in the 15th 
article of the directive 2011/24/EU related to the application of patients’ rights in 
cross-border health care. Despite HTA being a high-value speciality, the Turkish 
health care system has just newly developed its HTA perspective. Even though 
the system has been put in place recently and somehow fragmented between dif-
ferent institutions, HTA department in Turkey has conducted some research and 
reports regarding medical devices and pharmaceuticals some of which have not 
yet been concluded. It is also an active member of European Health Technology 
Assessment Network by having roles and responsibilities in working packages and 
authorship in projects. There is however a long way to go. In this paper, current 
situation of Turkish Health Technology Assessment capacity has been discussed 
and some information has been given regarding the efforts of cohesion between 
EU and international society.
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oBjectives: Cost-effectiveness evaluations of new products are currently entirely 
focused on incremental cost-effectiveness ratios (ICERs) calculated over the stand-
ard of care (SoCs), and do not take into consideration the cost-effectiveness inher-
ent/implicit of the SoCs themselves. We argue that the average cost-effectiveness 
of the SoC, expressed as a ratio of the difference in costs between the SoC and no 
treatment/best supportive care (NT/BSC), to the difference in outcomes, or the 
ACER, also merits regular evaluation to enable comparison of value being derived 
from healthcare spend across indications. Methods: To compute ACERs of SoCs, 
the costs associated with the SoC, and the benefits accrued were compared with 
that of NT/BSC applicable to each indication, based on inputs derived from previ-
ously accepted NICE evaluations. This exercise was carried out over 25 different 
indications spread across cancers, endocrine disorders, infectious diseases and 
immune disorders. results: ACERs varied considerably, from a low of £717 (influ-
enza in elderly) to the high seen in Prader-Willi syndrome of £148,675 with a mean 
of £33,700 and median of £27,190. ACERs in endocrinology ranged from £25,485 to 
£148,675, oncology from £9,367 to £38,641; infectious diseases from £717 to £13,710, 
and immune disorders from £22,728 to £90,156. discussion: Evaluation of reign-
ing ACERs of the SoCs in different indications helps in: a) getting an estimate of 
the economic value of the healthcare budget being spent in particular indications, 
and across the pharmaceutical product spectrum, b) calibrating and evaluating 
currently accepted threshold ICERs; and c) providing decision-makers with data 
that encourages them to consider permitting greater leeway for new products’ 
ICER acceptability in indications where the SOC’s ICER may be at the lower end 
of the range, and conversely, to tighten limits in indications where the current 
SoC’s ACER may be at the higher end of the range, and thereby narrowing the 
range.
